BRAF and hepatocellular carcinoma: Sorafenib and sorafenib tosylate (hits) are primarily known as potent inhibitors of Raf1 kinase, though it is also known to inhibit B‐Raf, VEGF receptors, and FGFR1.[54] These anti‐tumorigenic mechanisms of action led to sorafenib being used as a primary treatment for hepatocellular carcinoma.[55] However, its aggressive systemic use is associated with a number of adverse effects, including hand‐foot skin reactions and mild sensory neuropathy,[56, 57] suggesting it may not be a good candidate for antinociception.